T1	p 150 174	coronary atherosclerosis
T2	p 178 195	diabetic patients
T3	p 678 728	360 diabetic patients with coronary artery disease
T4	p 2449 2466	diabetic patients
T5	p 2559 2605	diabetic patients with coronary artery disease
T6	i 119 131	pioglitazone
T7	i 451 463	pioglitazone
T8	i 582 594	Pioglitazone
T9	i 747 759	pioglitazone
T10	i 763 774	glimepiride
T11	i 1146 1166	Pioglitazone-treated
T12	i 1568 1580	pioglitazone
T13	i 1758 1769	glimepiride
T14	i 2162 2182	pioglitazone-induced
T15	i 2356 2368	pioglitazone
T16	o 19 74	triglyceride/high-density lipoprotein cholesterol ratio
T17	o 150 174	coronary atherosclerosis
T18	o 925 954	Coronary atheroma progression
T19	o 1031 1118	changes in biochemical parameters , percent atheroma volume , and total atheroma volume
T20	o 1210 1256	high-density lipoprotein cholesterol ( HDL-C )
T21	o 1275 1335	glycated hemoglobin , triglycerides , and C-reactive protein
T22	o 1396 1437	percent atheroma volume and triglycerides
T23	o 1464 1488	triglyceride/HDL-C ratio
T24	o 1519 1538	glycated hemoglobin
T25	o 1598 1633	low-density lipoprotein cholesterol
T26	o 1661 1677	apolipoprotein B
T27	o 1709 1727	apolipoprotein A-I
T28	o 1882 1887	HDL-C
T29	o 1944 1957	triglycerides
T30	o 1995 2019	triglyceride/HDL-C ratio
T31	o 2070 2089	glycated hemoglobin
T32	o 2194 2212	triglyceride/HDL-C
T33	o 2245 2268	percent atheroma volume
T34	o 2286 2307	total atheroma volume
T35	o 2376 2400	triglyceride/HDL-C ratio
T36	o 2425 2445	atheroma progression